Please upgrade your browser.
Will you help to create greater awareness of kidney cancer and the need for a cure? Learn how you can win $1,000.00 and a FlipVideo camera for helping with this cause.
Reducing Risk Of Recurrence And A Stabilization In Incidence Of Renal Cell Carcinoma Will Limit Growth Of Drug-Treatment Opportunities
Projected improvements in recurrence-free survival and a discontinuation of the historically observed increases in the incidence rate of renal cell carcinoma (RCC) will limit growth of new drug-treatment opportunities for advanced disease in RCC.
The Cancer Nutrition Rehabilitation (cnr) program at the McGill University Health Centre is an interdisciplinary 8-week treatment program offering patients information, education, treatment, and support in areas such as diet, exercise, and rehabilitation, plus resources to address their psychosocial needs.
One of the tragi-comic sideshows of passing ObamaCare was the Democratic attempt to buy off the American Medical Association . . .
Axitinib significantly extended progression-free survival
"These data, in addition to positive tivozanib Phase 2 monotherapy data in patients with advanced kidney cancer, indicate significant potential for tivozanib across multiple tumor types.
|Powered by NeonCRM|